Press Releases

SAN FRANCISCO, July 8, 2019 /PRNewswire/ -- MedaRed, Inc., a biotechnology company focused on discovering and developing new therapeutics targeting fibrin today announced it had completed a $6.5 million seed financing round that was led by the Dementia Discovery Fund and Dolby Family Ventures.  MedaRed is founded upon the p

NEW YORK, July 8, 2019 /PRNewswire/ -- When a child needs recurring diagnostic x-rays, parents often worry about exposure to radiation. It's a concern for health professionals, as well. Children are more sensitive to the effects of radiation over time, and that's why Hospital for Special Surgery (HSS) recently acquired a fourth 2D/3D orthopedic imaging system that

HOUSTON, July 8, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it will release the cumulative 26-week patient d

PLANO, Texas, July 8, 2019 /PRNewswire/ -- Medaxis, a Swiss wound care company specializing in micro water jet technology, has been listed as a Top 10 Innovation for 2019 by the journal Podiatry Today for its "tissue-preserving, precision debridement device, debritom+".  This annual event highlights new and emerging innovations which advance

DUBLIN, Ohio, July 8, 2019 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2019 on August 8 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

ATLANTA, Ga., July 8, 2019 /PRNewswire/ -- Intent Solutions, an Atlanta-based company that provides technology to improve prescription drug safety an

RENTON, Wash., and REDMOND, Wash., July 8, 2019 /PRNewswire/ -- Microsoft Corp. and Providence St. Joseph Health today announced a multi-year st

MALVERN, Pa., July 8, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM) – Neuronetics, Inc., the developer of NeuroStar® Advanced Therapy, announced today that its depression outcomes registry has reached 3,223 evaluable patients, making it the largest outcomes registry in the world for Major Depressive Disorder (MDD). Launched in

CAMBRIDGE, Mass., July 8, 2019 /PRNewswire/ -- A new study published in the inaugural issue of the

Skyhawk will deploy its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases and cancer.  In exchange, Skyhawk is eligible to receive approximately $600 million per program target consisting of an upfront cash payment and, if Merck exercises its option, potential opt-in fees, milestone payments, as well as royalties on